Physicians should be on the lookout for chronic medical conditions, such as cold agglutinin disease (CAD), that may affect…
Articles by Joana Carvalho, PhD
APL-2, Apellis Pharmaceuticals’ investigational compound for the treatment of autoimmune hemolytic anemia (AIHA), increases the levels…
Patients with cold agglutinin disease (CAD) are twice as likely to die of their disease within the first five years…
The profile of patients with mixed autoimmune hemolytic anemia (MAIHA) must be carefully analyzed to facilitate diagnosis and disease management,…
APL-2, Apellis Pharmaceuticals‘ investigational compound for the treatment of autoimmune hemolytic anemia (AIHA) and other complement system diseases,…
Despite being extremely rare, cold type autoimmune hemolytic anemia, or cold agglutinin disease (CAD), should be considered in patients with…